Lithium is commonly used in psychiatry for mood stabilization. Lithium treatment results in neutrophilia, increased platelets and increased circulating CD34 þ haematopoietic stem cells, HSC. This paper outlines the newly discovered mechanism by which this occurs. Glycogen synthase kinase-3, GSK-3, phosphorylates and thereby inactivates hypoxia-induced factor-1, HIF-1. HIF-1 is a transcription factor triggering transcription of multiple genes related to adaptation to hypoxia, among which is CXCL12. CXCL12 forms the primary homing gradient for CD34 þ HSCs towards the hypoxic, trophic bone marrow niche to which they must go to thrive. Lithium inhibits GSK-3 thereby increasing active HIF-1 that results in a stronger CXCL12 homing gradient. Trophic niche function is enhanced, ultimately resulting in increased production of neutrophils, platelets and CD34 þ cells. Sitagliptin is a new drug to treat diabetes that coincidentally inhibits destruction of CXCL12. Thus, lithium and sitagliptin enhance CXCL12 by different paths, potentially increasing trophic niche function. Awareness of this path is important in HSC transplantation.
Introduction
This paper pieces together recent research showing the probable mechanism of action of lithium by which it raises neutrophil counts when used in humans to treat psychiatric illness. Understanding this mechanism has importance for bone marrow transplantation practice. The path described is a central component active in control of normal and malignant haematopoiesis. Two drugs of particular interest, one old-lithium, one new-sitagliptin, have potential to particularly enhance post transplant engraftment.
Lithium ion, delivered as lithium chloride or lithium carbonate, has been used to treat brain function problems for over a century. As of 2007, lithium remains in common use worldwide to treat mood cycling and as adjunct in treatment of unipolar depression.
1,2 Lithium has curious selective antisuicidal activity across diagnoses. 2 Although treatment with lithium carries a risk of hypothyroidism and rare renal-function decrement, these effects are not seen with short-term (several weeks) use. Short-term effects that could be expected are reversible tremor and some risk of fatigue and foggy mentation.
Early in psychiatry's use of lithium, increases in circulating neutrophils and granulocyte colony formation in vitro were noted. 3, 4 Lithium induces neutrophilia in normal, non-psychiatric volunteers. 5 Mice show increased marrow granulopoiesis and haematopoietic stem cell (HSC) count days after starting lithium. 5 Circulating CD34 þ HSC are increased in humans during lithium treatment. 6, 7 GSK-3/HIF-1/CXCL12 AXIS Akt to GSK-3 Figure 1 depicts an envisioned chain of events linking lithium to neutrophilia and increased CD34 þ cells:
Glycogen synthase kinase-3, GSK-3, is present in two forms, GSK-3a of 51 kDa and GSK-3b of 47 kDa. Although coded by two different genes, they have 98% homology. GSK-3 was originally identified as a phosphorylating inhibitor of glycogen synthase, 8 but is now known to phosphorylate dozens of target proteins, some resulting in target protein activation (cAMP response element binding protein is an example), but more commonly in loss of function. 8 GSK-3 itself is phosphorylated by Akt (also known as protein kinase B) upon which many signalling path converge. Phosphorylated GSK-3 is inactive and marked for proteosomal degradation.
Lithium inhibits GSK-3 (a) at 2 meq/l, GSK-3 is directly inhibited by 50%, but (b) at 0.8 meq/l, Akt phosphorylation of GSK-3 is greatly facilitated.
9,10 Lithium levels of 2 meq/l are poorly tolerated, of questionable safety and rarely and only inadvertently achieved (and are urgently corrected downward). Lithium levels are commonly kept around 0.8-1.2 meq/l, which is usually well-tolerated. Lithium inhibition of GSK-3 generates neutrophilia by shifting a basic balance point in haematopoiesis.
The balance point: GSK-3 to HIF-1 Active GSK-3 phosphorylates the transcription factor hypoxia-inducible factor-1, HIF-1.
11 Phosphorylated HIF-1 is sent to the proteosome for degradation. HIF-1 is a heterodimer of 120 kDa HIF-1a and 91 kDa HIF-1b. 12 Among the wide-ranging transcription-initiating activities of HIF-1, many are genes associated with adaptation to low oxygen tension, such as that for erythropoietin and vascular endothelial growth factor. 12, 13 Under normoxic conditions, HIF-1a is proline-hydroxylated when it gains high affinity for von Hippel-Lindau factor leading to ubiquitination and proteosomal degradation, another and probably the primary path for downregulating HIF-1. 12, 14, 15 Bone marrow trophic, hypoxic pockets attract and retain HSC indirectly via HIF-1 among other paths. 14, 16, 17 HIF-1 to CXCR4-CXCL12 system CXCR4 is a 45 kDa outer cell membrane receptor for the 8 kDa chemokine CXCL12 (synonymous with the older term stromal-derived factor-1). 16, 17, 18 HIF-1 interacts with the promoter region of the CXCR4 gene, stimulating its transcription 19, 20 and with the promoter region of the CXCL12 gene, stimulating its transcription. 21, 22 HIF-1 also upregulates vascular endothelial growth factor expression 23, 24 contributing to marrow neoangiogenesis.
A concentration gradient of CXCL12 forms a homing signal for HSC to find their hypoxic, trophic bone marrow niche.
14,15,17 CXCL12 also forms a primary homing signal for CXCR4 bearing circulating cancer cells to find an hypoxic, trophic niche. 18, 25, 26 Hence, predilection for CXCR4 bearing cancers to metastasize to high-concentration CXCL12 areas like bone.
Summarizing: hypoxia drives HIF-1 levels up, promoting CXCL12 gradient establishment towards hypoxic, trophic marrow areas. GSK-3 mediates one of the two known degradation paths for HIF-1. Lithium inhibits GSK-3 function thereby indirectly increasing the attractive CXCL12 gradient towards hypoxic marrow trophic niche where HSC can thrive. This is reflected by increased marrow trophic niche function: peripheral neutrophilia, increased platelets and increased CD34 þ counts.
CXCL12 and CD26/DPP-4 and the new class of medicines: gliptins CD26 was originally identified as an activated T-cell antigen, widely expressed on epithelia, endothelia and T lymphocytes, especially CD45Ro þ . CD26 is absent in B cells, yet is expressed on most normal T cells and malignant neoplasms of T-cell origin. Co-stimulation by CD26 is crucial to antigen-driven T-lymphocyte activation.
27
CD26 is synonymous with dipeptidyl peptidase-4, DPP-4 (EC 3.4.14.5), a 110 kDa transmembrane protease that preferentially removes the two N-terminal amino acids of peptides with a penultimate proline or alanine. CXCL12 is one such peptide. Empirically, DPP-4 is found to mediate the primary catabolic step in CXCL12 inactivation. 28, 29 It is here that G-CSF (filgrastim) acts when used prior to HSC harvest apharesis for bone marrow transplantation procedures. G-CSF increases the proteolytic nature of the trophic bone marrow niche by upregulating DPP-4. This decreases CXCL12 gradient, loosening the grip on CD34 þ cells that then flood the circulation. 16, 28, 29 Glucagon-like peptide-1 is a 29-amino acid, 3.3 kDa peptide synthesized within ilium gut wall in response to food, that is also readily cleaved by DPP-4. 30 Since glucagon-like peptide-1 stimulates insulin secretion by pancreatic islet b cells, inhibitors of DPP-4 lower postprandial glucose levels in type II diabetes. 30 Sitagliptin (Januvia) is the first oral DPP-4 inhibitor approved and marketed in USA and the EU for diabetes treatment.
The potential value of sitagliptin to haematology and bone marrow transplantation was realized quickly. 29, 31 By inhibition of CXCL12 degradation, sitagliptin was predicted to increase homing of transplanted HSC, particularly in cases when engraftment is failing. 29, 31 Other related DPP-4 inhibitors such as vildagliptin, saxagliptin and denagliptin 30 are in late-stage trials for treating diabetes and are expected to be marketed soon.
After HSC transplantation, G-CSF is used to support the transplanted HSC until engraftment is established. G-CSF upregulates DPP-4 16, 28, 29 and this upregulation is a desired effect of G-CSF during harvest. Use of lithium and/or sitagliptin may blunt this aspect of G-CSF during engraftment phase use.
Conclusions
Lithium inhibits GSK-3 by two separate paths. GSK-3 phosphorylates HIF-1, thereby enhancing HIF-1's destruction in the proteosome. By inhibiting GSK-3 function, lithium increases active HIF-1. HIF-1 is a transcription factor that upregulates transcription of vascular endothelial growth factor, CXCR4 and CXCL12 among many other genes. CXCL12 forms an important gradient for HSC homing to a hypoxic, trophic bone marrow niche. Increased homing ultimately is reflected in lithium-related increased circulating CD34 þ HSC, neutrophils and platelets.
Sitagliptin is new diabetes treatment that inhibits DPP-4. Since DPP-4 happens incidentally to be the primary catabolic step in destroying CXCL12, sitagliptin may complement lithium in increasing strength of HSC homing to the trophic bone marrow niche. This would be particularly useful during engraftment phase G-CSF use.
